Figure 3. The experimental schedule used for assessing the synergistic anticancer efficacy of MH-30 and cisplatin in melanoma-bearing mice. B16F10 melanoma cells (2×105/mouse) were inoculated subcutaneously into the left femoral region of mice. MH-30 was given daily at 100 mg/kg B.W. until the end of the experiment. Cisplatin was intraperitoneally injected at 3 mg/kg B.W. on days 7, 8, 13, 14, 19 and 20 (total six injections).